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Amyotrophic lateral sclerosis (ALS), which was described since
1869 by Jean Martin Charcot, is a devastating neurodegenera-
tive disease characterized by the selective and progressive loss of
upper and lower motor neurons of the cerebral cortex, brain-
stem and the spinal cord. The result of this loss is a progres-
sive and irreversible paralysis leading to a complete incapacity
of movements and finally to respiratory failure, but the cog-
nitive functions are not affected and is not merely the result
of aging because may occur at young adult ages. There is still
no treatment, prevention or reliable biomarkers of ALS and
it is clear that this could only be accomplished, as for other
neurodegenerative diseases, through the knowledge of the cel-
lular and molecular pathophysiological mechanisms involved.
Research on such mechanisms is, therefore, essential. Although
progress in neurochemical, physiological, genetic and clinical
investigations in the last decades has identified several cellu-
lar processes and mechanisms that seem to be involved in the
neuronal death, such as glutamate receptors-mediated excito-
toxicity, disruption of spinal inhibitory circuits, inflammatory
events, axonal transport deficits, oxidative stress, mitochondrial
dysfunction, energy failure, intracellular Ca2+ dishomeostasis,
protein aggregation and misfolding, changes in gene expression,
astrocytes alterations, and non-cell autonomous toxic factors,
the understanding of the origin and temporal progress of the
disease is still incomplete and insufficient. Clearly, there is a
need of further experimental models and approaches to discern
the importance of such mechanisms and to discover the factors
that determine the selective death of motor neurons charac-
teristic of ALS, in contrast to other neurodegenerative diseases
such as Parkinson’s and Alzheimer’s disease in which other neu-
ronal types located in other CNS regions are predominantly
affected.
The only known cause of the disease is associated with genetic
mutations, mainly in the gene encoding superoxide dismutase 1
(SOD1) which is the most frequent case of familial ALS (FALS),
representing about 20% of cases of FALS, albeit over one hun-
dred mutations have been described in FALS. In contrast, there is
no known cause of the sporadic form of ALS (SALS), that com-
prises >90% of all cases, although several other mutations have
recently been identified also in SALS. Both ALS types show sim-
ilar histopathological and clinical characteristics, and in spite of
numerous investigations using tissue from ALS patients and rel-
evant advances in the design of several experimental models of
motor neuron degeneration, it has not been possible to establish
a clear cause-effect relationship regarding the loss of motor neu-
rons or the motor alterations characteristic of the disease, such as
fasciculations, spasticity, and progressive paralysis.
Studies in vitro in cell cultures, tissue slices or organotypic
preparations have given useful information regarding the cellu-
lar and molecular mechanisms of motor neuron death. However,
except for transgenic rodents expressing mutant forms of human
SOD1 (mSOD1), which are the most extensively used model
in vivo in spite of the low frequency of FALS as compared to
SALS, experiments in living animals are scarce. These models
should reflect more closely the situation in the human dis-
ease, provided that the symptoms and their development during
time mimics as close as possible those of the human disease.
It is therefore necessary to correlate the experimental findings
in vitro with those in vivo, as well as those obtained in genetic
models with those in non-genetic models, in order to design
and test therapeutic strategies based on the results obtained.
The aim of the original research articles and reviews of this
Research Topic is to contribute to the progress in this important
field.
Genetic alterations, including epigenetic and gene expres-
sion changes in both neurons and glial cells, mainly astro-
cytes, as well as studies ex vivo of nervous and muscular tissue
from ALS patients and from mutant SOD1 transgenic mice,
constitute the majority of the articles of this Research Topic.
Such changes have been studied in whole tissue, microdis-
sected isolated cells and subcellular fractions, mainly mitochon-
dria, using several molecular biology techniques, not only in
the CNS but also in muscle of mSOD mice, and have shown
that there is a large variety of alterations in gene expression.
These results are the subject of the articles by Heath et al.
(2013); Crippa et al. (2013); de Oliveira et al. (2013), and
Wong et al. (2013), which amply cover the literature on this
subject and also provide new data, such as the relation of
some of these genetic alterations with autophagy, epigenetic
changes of mitochondrial DNA in the spinal cord and in mus-
cle, and comparative analysis of early and late gene expression
changes.
The role of astrocytes and microglia frommSODmice in non-
cell autonomous processes, including the release of toxic factors,
is studied by Rojas et al. (2014) and Trias et al. (2013), with a
useful ex vivo approach. Related studies by Staats et al. (2013)
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and Bowerman et al. (2013) show the involvement of microglia
and neuroimmunological events in the progress of ALS and sug-
gest possible therapeutic strategies. The molecular modifications
of mSOD1 protein, and how such alterations, like oxidation,
aggregation or misfolding, result in its toxicity, are reviewed by
Furukawa (2013); Rotunno and Bosco (2013), and Ogawa and
Furukawa (2014). Again in mSOD1 mice but with a different
approach, Mòdol et al. (2014) show a possible role of the potas-
sium chloride cotransporter 2 in spasticity, including results on
the role of spinal inhibitory interneurons.
A partial protective effect of the NMDA receptor antagonist
gacyclidine on the motor deficits in mSOD1 mice is shown by
Gerber et al. (2013), and the role of trophic factors in the modu-
lation of motor neurons activity as well as their protective effect
in several models of ALS, is reviewed by Tovar-y-Romo et al.
(2014) and Lladó et al. (2013). It is emphasized in particu-
lar the potent protective action of vascular endothelial growth
factor (VEGF). Other potential protective agents, reviewed by
Lazo-Gómez et al. (2013), are activators or inhibitors of histone
deacetylases, enzymes that regulate gene expression and may be
involved in motor neuron degeneration.
A general panorama of the role of lipids in ALS is presented
by Schmitt et al. (2014), with emphasis on energy and signaling
mechanisms. In a more systemic approach, Garbuzova-Davis and
Sanberg (2014) review the vascular changes that may alter blood
brain barrier and thus be involved in the pathogenesis of ALS, as
compared to the transgenic rodent models.
The large amount of information contained in this Research
Topic, in both the comprehensive reviews and the original
research articles, reflect the considerable advances made but at
the same time the necessity for new experimental models and
approaches for gaining clearer responses to several still unre-
solved questions, such as the following: why the clinical man-
ifestations of motor neuron death in both FALS and SALS
appear in young adulthood but are not age-related, particu-
larly the former, in spite of the fact that genetic alterations
are present since the beginning of individual life? Why the
motor neuron degeneration progresses rapidly after the initial
symptoms appear? What is the cause of SALS? It is now clear
that the loss of motor neurons in ALS is multifactorial, but
many of the deleterious factors seem to occur also in other
neurodegenerative diseases like Parkinson’s and Alzheimer’ dis-
ease; then, maybe the crucial question to be answered is: what
determines the predominant, if not totally selective character-
istic death of motor neurons in ALS, sparing other neuronal
types?
In spite of these unsolved questions, it is clear that the available
information permits the design and testing of diverse therapeutic
strategies that have already shown valuable results in delaying or
preventing neuronal death in experimental models, for example
the administration of VEGF. However, the translation of pos-
sibly effective treatments from experimental procedures to ALS
patients represents different problems, such as the routes, doses
and timing of administration and the potential undesirable col-
lateral effects. Because we have no indication or biomarker of the
susceptibility to ALS and of when will it manifest, it is extremely
difficult to prevent or treat the disease. When symptoms have
already started and the diagnosis is made it is probably too late
to impede the progression of neuronal degeneration. A verifiable
resolution of the above questions seems a requisite for efficient
and reliable treatments or prevention of this dreadful disease.
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